To illustrate, while CD19 stands as a widely employed target for CAR-T cell therapy in the context of treating acute lymphoblastic leukemia (ALL), it is noteworthy that not all B cell malignancies express CD19 uniformly. Here, CD19 is linked to acute lymphoblastic leukemia.